Platforms

ImmBio’s business is focused on the development of products which provide protection and treatment against pathogens by activating an immunological response mediated by dendritic cells. There are two complementary routes deployed to achieve this during the normal cause of infection: ImmBio has platform technology covering both.

• Based on significant recent insights into the pivotal role of Heat Shock Protein Complexes (“HspCs”) in the immune system, ImmBio has developed and patented new vaccine and therapeutic technology. The resultant products have:
  • Can be developed with or without prior knowledge of key pathogen antigens
  • Confer strong broad, polyclonal protection, presenting multiple antigens
  • Do not require the addition of adjuvants, with Hsps stimulating an innate response and with Hsps binding to dendritic cells, hence able to load their cargo into normal pathways
  • Good safety profile

• ImmBio has a license agreement for ImmunoBodies™ technology with Scancell Ltd for certain anti-infective targets. These are antibody-antigen fusion protein complexes which, like HspCs, stimulate the immune system via dendritic cells. The resultant products have:
  • Utilise a single or finite number of known antigens
  • Can be rapidly developed once a target antigen has been identified
  • Rapid manufacturing cycle time and low cost of goods
  • Utilise expression systems regulatory bodies are familiar with
  • Like HspCs, do not require adjuvants and have good safety profiles.

A primer on the role of ImmBio’s vaccines in preventing and limiting infections is available: